Peripheral Blood Mononuclear Cells Expression Levels of miR-196a and miR-100 in Coronary Artery Disease Patients. (17th November 2021)

• Record Type: Journal Article
• Authors: Saadatian, Zahra; Nariman-Saleh-Fam, Ziba; Khaheshi, Isa; Mansoori, Yaser; Daraei, Abdolreza; Ghaderian, Sayyed Mohammad Hossein; Omrani, Mir Davood
• Is Part Of: Immunological investigations. Volume 50:Number 8(2021)
• Page Start: 914
• Page End: 924
• Publication Date: 2021-11-17
• Subjects: Microrna -- coronary artery disease -- miR-196a -- miR-100 -- peripheral blood mononuclear cell; Immunology -- Periodicals; Immunochemistry -- Periodicals; Cellular immunity -- Periodicals; Communicable diseases -- Periodicals; 616.079
• DOI: 10.1080/08820139.2020.1791177
• Languages: English
• ISSNs: 0882-0139

Abstract

ABSTRACT: As a chronic inflammatory disease, coronary artery disease (CAD) is a common cause of death worldwide. Dysregulation of microRNA expression levels in peripheral blood mononuclear cells (PBMCs) may contribute to CAD and serve as a potential diagnostic biomarker. Here, we evaluated PBMC expression of two CAD-related inflammatory miRNAs, miR-196a and miR-100, in PBMCs of CAD patients with significant stenosis (CAD, n: 72), patients with insignificant coronary stenosis (ICAD, n: 30), and controls (n: 74) and checked whether they can segregate study groups. MiRNA expression was evaluated using the standard stem-loop RT-qPCR method. MiR-196a expression was downregulated in ICAD compared to CADs and healthy groups. MiR100 expression levels were not different between groups. The receiver operating characteristic (ROC) curve analysis acquainted that miR-196a expression levels in PBMC could segregate CAD individuals or any of its clinical manifestations (i.e. unstable angina, stable angina, acute myocardial infarction) from ICADs. In conclusion, this study reported a distinct miR-196a expression pattern in PBMCs of all patient groups and recommended a biomarker potential for miR-196a in discriminating ICADs from CADs or healthy controls.